Amgen’s Pavblu has been the most successful US biosimilar launch by any manufacturer to date, with more than $600 million in net sales in 2025.
The February 3rd earnings report released by Amgen underscore the major success of its Pavblu launch, the first biosimilar competitor to Eylea. For the full year 2025, US net sales were $691 million, the company’s most successful biosimilar launch to date. In the fourth quarter of 2025 alone, Amgen registered $254 million in sales, putting it on a potential path to $1 billion in annual sales, though several other biosimilar competitors will enter the market in 2026.
The maker of the reference product, Regeneron, confirmed 42% lower sales of Eylea, to $2.38 billion in the US, but also 36% greater sales of Eylea HD, to $1.64 billion.
On a net sales basis—not a prescription volume basis—it would appear that Amgen has a 30% share of the aflibercept non-HD market and a 9% share of the entire aflibercept franchise market. These data support the greater story of this aflibercept biosimilar launch success and the race by Regeneron to move prescriptions to the Eylea HD formulation, before payers prefer the less-expensive biosimilar competition.
The Pavblu launch success was driven by Amgen’s decision to begin marketing the first aflibercept biosimilar at risk, and it will remain the only aflibercept biosimilar on the market until the second half of 2026.
In Other Biosimilar News
Here’s more news on an aflibercept biosimilar launch—this one by Samsung Bioepis. According to a press release, the company and the reference manufacturer Regeneron announced an agreement February 12, allowing the US launch of Samsung Bioepis’ Opuviz in January 2027. At that time, Samsung will have both ranibizumab and aflibercept biosimilars in its ophthalmologic portfolio.
This article was written by our Director of Content, Stanton Mehr. Stan is has been writing commentary and reporting news about the biosimilar industry since the submission of the first biosimilar 351(k) application to the FDA 14 years ago. Since that time, BR&R has been tracking the US biosimilar marketplace, with the industry’s original, comprehensive and updated database of biosimilar filings with the FDA.